prognosis
-
February 22, 2020
Predicting Prognosis in Glioblastoma Bookmark
George Lundberg, MDArticle from The Pathologist curated by Editor in Chief George Lundberg, MD, who notes:
Liquid biopsy shows surprising apparent prognostic value in glioblastoma multiforme (GBM).
Go to full article published by The Pathologist.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
September 16, 2019
Fixed and Variable Factors that Impact a Brain Tumor Patient’s Prognosis
George Lundberg, MDA Q&A with Burt Nabors, MD, Professor and Director of the Division of Neuro-oncology at the University of Alabama, Birmingham, and a member of the Cancer Commons Brain Tumor Advisory Board; bnabors@uabmc.edu Q: Primary brain gliomas can be devastating, often deadly, malignancies. Obvious prognostic factors include whether they are grade 1, 2, 3, or 4; their extent of growth prior to diagnosis (stage); and… Read more »
-
August 15, 2019
Can Deep Learning Algorithms Speed Up Lung Cancer Care? Bookmark
George Lundberg, MDExcerpt from Cancer Network:
“A deep learning approach to assessing cancer outcomes appears feasible, according to results of a study in patients with lung cancer. Machine curation yielded similarly accurate assessments of progression and times to improvement and response compared with human counterparts. This development could speed up oncology care processes.
” ‘Important clinical end points, such as response to therapy and disease progression, are often recorded in the EHR [electronic health record] only as unstructured text,’ wrote authors led by Kenneth L. Kehl, MD, MPH, of the Dana-Farber Cancer Institute in Boston. Standards such as RECIST are not routinely applied outside of clinical trials.”
Go to full article published by Cancer Network.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
September 25, 2018
Tool Predicts Risk for Late Breast Cancer Recurrence Bookmark
Emma Shtivelman, PhDExcerpt from Healio:
“An online prognostic tool accurately determined the risk for late distant recurrence among women with ER-positive breast cancer, according to a single-arm, prospective study.
“The Clinical Treatment Score post-5 years (CTS5) tool could be used to determine whether patients should continue endocrine therapy 5 years after initial treatment.”
Go to full article published by Healio on Sep 19, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.